# of Displayed Technologies: 10 / 14

Applied Category Filter (Click To Remove): Therapeutics


Categories

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Kudryashova, Elena
  • Licensing Officer: Flammang, Ann Marie

Novel compositions of nanoparticles for nucleic acid therapeutic delivery
TS-040254 — Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.
Lipid-based nanoparticles (LNPs) have been extensively utilized in nucleic acid delivery. However, there are a number of challenges associated with LNP formulation. It is difficult to make sub-100-nm LNPs with a high nucleic acid concentration by traditional self-assembly methods. LNP synthesis ty…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Development of novel furano-parthenolides for human leukemia treatment
TS-038998 — Parthenolide analogues derived from plants could be effective in treating leukemia or supplementing other treatments.
The American Cancer Society estimates that in 2017 there will be about 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the United States. Chemotherapy has improved, but further development is needed to improve the efficacy of this treatment, and cancers can develop multidrug resi…
  • College: College of Pharmacy
  • Inventors: Ren, Yulin
  • Licensing Officer: Flammang, Ann Marie

Use of Gene Product to Treat Nerve Injury and Sarcopenia
TS-037778 — A novel method using the overexpression of survival motor neuron protein to improve motor unity synaptic repair and restore/protect muscle size and function due to sarcopenia
Sarcopenia, the age-related wasting and loss of strength, is an important neuromuscular problem of aging. It affects up to 50% of individuals by the 8th decade, and can lead to impaired mobility, loss of independence, and increased risk of mortality. The neuromuscular system is comprised of groups…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Arnold, William; Kaspar, Brian; McGovern, Vicki
  • Licensing Officer: Flammang, Ann Marie

Thermogenic Biologicals for Obesity Treatment
TS-037747 — Identification and use of novel adipokines for reduction of visceral fat using thermogenesis.
Obesity as a result of an increase in intra-abdominal (or visceral) fat is an independent risk factor for major diseases such as type 2 diabetes and cardiovascular diseases. Risk is increased with higher levels of intra-abdominal fat due to increases in insulin resistance and chronic inflammation,…
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: Flammang, Ann Marie

Thermogenic Biologicals Treatment of Obesity and Improvement of Insulin Resistance
TS-037746 — Innovative thermogenic biologicals, methods of delivery, and combinational therapy for the treatment of abdominal obesity
Obesity as a result of an increase in intra-abdominal (or visceral) fat is an independent risk factor for major diseases such as type 2 diabetes and cardiovascular diseases due to increases in insulin resistance and chronic inflammation. Accumulation of intra-abdominal fat, even in non-­obese …
  • College: College of Education & Human Ecology
  • Inventors: Ziouzenkova, Ouliana; Parquette, Jonathan
  • Licensing Officer: Flammang, Ann Marie

Antisense Oligonucleotide Development for Treatment of Spinal Muscular Atrophy
TS-037741 — The SMN2 gene contains sequences that regulate the level of inclusion of SMN exon7 in SMN mRNA, and some of these act in a negative manner. Antisense oligonucleotides to block the negative regulating protein binding to these sites can increase inclusion of SMN exon 7 and thus, the amount of SMN being produced.
Spinal muscular atrophy (SMA) is a genetic disorder that affects the control of muscle movement. It is caused by a loss of motor neurons in the spinal cord and brainstem, leading to weakness and atrophy in the muscles used for walking, crawling, sitting up, and head movement. In severe instances, …
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; McGovern, Vicki; Prior, Thomas
  • Licensing Officer: Flammang, Ann Marie

Antitumor Arylnaphthalene Lignan Glycosides
TS-037721 — A group of potential antitumor arylnapthalene lignan glycosides, which may be developed as novel cancer chemotherapeutic agents.
Nearly 1 in 6 deaths worldwide are from cancer. Although significant advancements have been made towards treatment and control of cancer progression, there is still a need for improvement and enhancement of available treatments. For the last 50 years, natural therapies, such as plant-derived produ…
  • College: College of Pharmacy
  • Inventors: Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Flammang, Ann Marie

Lipid Nanoparticles for Therapeutic Delivery of Anti-miRs and miRs
TS-037707 — An efficient delivery vehicle for therapeutic oligonucleotides with high efficiency.
MiRNA or miRs are small non-protein coding RNA which are capable of regulating mRNAs in multiple biological pathways, including those involved in cancer development and wound healing. Antagomirs, also known as anti-miRs, inhibit miR activity and could be used to develop therapeutics for interventi…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

A Method of Creating FKBP-Small Molecule Composite Surfaces as Inhibitors of Protein-Protein Interactions
TS-037677 — A mechanism by which the inhibiting efects of drugs and other molecules on protein-protein interactions can be measured.
Protein-protein interactions (PPIs) occur when two or more proteins bind together, and they represent a large group of drug targets. However, PPIs are difficult to disrupt because they usually involve large, two-dimensional target surfaces. Conventional small molecule drugs can bind with high affi…
  • College: College of Medicine (COM)
  • Inventors: Briesewitz, Roger; Pei, Dehua; Wu, Xianghong
  • Licensing Officer: Flammang, Ann Marie

Show More Technologies

PDF

Loading icon